Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2023 Sep;30(5):264-267.
doi: 10.1136/ejhpharm-2021-002877. Epub 2021 Oct 14.

Effectiveness of antithrombotic prophylaxis in hospitalised patients with SARS-CoV-2 infection

Helena Quiros Ambel  1 , Paloma Crespo-Robledo  2 , Karmele Arribalzaga Juaristi  3 , Isabel Plo-Seco  2 , Jose Javier Martínez Simón  2 , Elia Pérez Fernández  4 , Monserrat Perez Encinas  2
Affiliations
Observational Study

Effectiveness of antithrombotic prophylaxis in hospitalised patients with SARS-CoV-2 infection

Helena Quiros Ambel et al. Eur J Hosp Pharm. 2023 Sep.

Abstract

Background: Antithrombotic prophylaxis in hospitalised patients with SARS-CoV-2 acute infection has increased. Currently, most of the evidence relates to patients in intensive care units; however, there is little information on patients admitted to hospital wards and there is no consensus protocol on thromboprophylaxis during admission and after discharge.

Objective: To assess the effectiveness of antithrombotic prophylaxis in patients admitted with COVID-19 and 30 days after discharge.

Method: A prospective observational study was conducted of patients admitted with COVID-19 in which the hospital thromboprophylaxis protocol was applied, classifying the patients as having a standard or high risk of thrombosis. Pharmacists performed a daily follow-up and actively intervened during admission and at discharge. The main outcome measure was the global incidence of symptomatic venous thromboembolism (VTE) related to hospitalisation.

Results: A total of 113 patients were included, 98.23% of whom were admitted to a hospital ward. The incidence of hospital-acquired VTE was 1.77%. In 75.22% of the subjects, thromboprophylaxis was adjusted to the protocol during admission. A total of 23 pharmaceutical interventions were conducted, with an adherence of 52.17%. At discharge, 94.28% of the patients who had no haemorrhage and ≥4 points on the Padua Prediction Score required thromboprophylaxis, aligning with the protocol. The global incidence of haemorrhagic events during the follow-up period was 0.88%.

Conclusion: The incidence of hospital-acquired VTE was lower than that described in the literature. Although it cannot be certain that it is directly related to the instituted protocol, the data can show that the management of prevention of VTE is being optimally performed at the hospital. Long-term studies are needed to evaluate the incidence after discharge, as well as to agree on a specific protocol in the COVID-19 population for the prevention of these events during hospitalisation and post-discharge.

Keywords: COVID-19; anticoagulants; drug-related side effects and adverse reactions; hospital; pharmacy service; thromboembolism.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

References

    1. Llau JV, Ferrandis R, Sierra P, et al. Recomendaciones de consenso SEDAR-SEMICYUC sobre el manejo de las alteraciones de la hemostasia en los pacientes graves con infección por COVID-19. Rev Esp Anestesiol Reanim 2020;67:391–9. 10.1016/j.redar.2020.05.007 - DOI - PMC - PubMed
    1. SETH . Recomendaciones de tromboprofilaxis y tratamiento antitrombótico en pacientes con COVID-19, 2020.
    1. López-Reyes R, Oscullo G, Jiménez D, et al. Riesgo trombótico y COVID-19: revisión de la evidencia actual para Una mejor aproximación diagnóstica y terapéutica. Arch Bronconeumol 2021;57:55–64. 10.1016/j.arbres.2020.07.033 - DOI - PMC - PubMed
    1. Páramo JA. Scores and algorithms in haemostasis and thrombosis [Internet], 2014. Available: https://www.seth.es/images/files/Practical-Manual-Scores-Algorithms-Haem...
    1. Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis . Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005;3:692–4. 10.1111/j.1538-7836.2005.01204.x - DOI - PubMed

Publication types